Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 2Phase NA 1

Status

Unknown 8Completed 8Terminated 2Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Esophageal Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Tegafur × Clear all
NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Sunshine Lake Pharma Co., Ltd.

Phase 3 Recruiting
416 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT03941561 2019-05-31

S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)

Fudan University

Phase 3 Recruiting
1,006 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡